Dementia, Lewy Body (DLB)

Categories: Eye diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 58 26 13
Lewy Body Dementia 58 12 54 26 55 76 38 30 6 15 41 17
Lewy Body Disease 12 54 26 56 44 45 74
Diffuse Lewy Body Disease 58 12 54 26 76
Dementia with Lewy Bodies 12 77 26 55 15
Dlb 58 54 26 76
Autosomal Dominant Diffuse Lewy Body Disease 54 74
Diffuse Lewy Body Disease with Gaze Palsy 76
Lewy Body Variant of Alzheimer Disease 76
Dementia, Lewy Body, Susceptibility to 6
Lewy Body Dementia, Susceptibility to 58
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 26
Lewy Body Type Senile Dementia 76
Dysphasic Dementia Hereditary 76
Cortical Lewy Body Disease 76
Dementia Lewy Body 76
Lewy Bodies 30
Lbd 26



autosomal dominant

onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


dementia, lewy body:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:12217
OMIM 58 127750
KEGG 38 H00066
ICD9CM 36 331.82
MeSH 45 D020961
NCIt 51 C84826
SNOMED-CT 69 80098002
ICD10 34 G31.83

Summaries for Dementia, Lewy Body

NINDS : 55 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 3, autosomal dominant and multiple system atrophy 1, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Donepezil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and eye, and related phenotypes are dementia and parkinsonism

Disease Ontology : 12 A dementia and a synucleinopathy that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Genetics Home Reference : 26 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed.

NIH Rare Diseases : 54 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

OMIM : 58 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

MedlinePlus : 44 Lewy body disease is one of the most common causes of dementia in the elderly. Dementia is the loss of mental functions severe enough to affect normal activities and relationships. Lewy body disease happens when abnormal structures, called Lewy bodies, build up in areas of the brain. The disease may cause a wide range of symptoms, including Changes in alertness and attention Hallucinations Problems with movement and posture Muscle stiffness Confusion Loss of memory Lewy body disease can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. Lewy body disease usually begins between the ages of 50 and 85. The disease gets worse over time. There is no cure. Treatment focuses on drugs to help symptoms. NIH: National Institute of Neurological Disorders and Stroke

UniProtKB/Swiss-Prot : 76 Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

Wikipedia : 77 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in behavior, cognition and... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 3, autosomal dominant 32.3 SNCAIP SNCA PRKN PARK7 MAPT LRRK2
2 multiple system atrophy 1 32.2 TH SNCB SNCA SLC6A3 RPS27A PRKN
3 corticobasal degeneration 32.1 RPS27A MAPT LRRK2 GBA
4 perry syndrome 31.9 TH SNCA SLC6A3 SLC18A2
5 parkinson disease 2, autosomal recessive juvenile 31.9 SNCA PRKN PARK7 LRRK2
6 posterior cortical atrophy 31.1 APOE MAPT
7 pure autonomic failure 30.7 TH SNCA MAOB ACHE
8 dysautonomia 30.5 SNCA PRNP GBA
9 synucleinopathy 30.5 TH SNCG SNCB SNCAIP SNCA SLC6A3
10 aphasia 30.4 SNCA PRNP MAPT APP APOE
11 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.4 RPS27A MAPT
12 gaucher's disease 30.4 GBA PRKN SNCA
13 essential tremor 30.4 SNCA SLC6A3 PRKN LRRK2
14 vascular dementia 30.4 MAPT BCHE APP APOE ACHE
15 alzheimer disease 2 30.3 MAPT BCHE APP APOE
16 tremor 30.3 SNCA PRKN MAPT LRRK2 GBA
17 cerebral amyloid angiopathy, cst3-related 30.3 PRNP MAPT APP APOE
18 rem sleep behavior disorder 30.3 SNCA SLC6A3 RPS27A LRRK2 ACHE
19 early-onset parkinson's disease 30.3 SNCA PRKN PARK7 LRRK2 GBA
20 creutzfeldt-jakob disease 30.3 PRNP MAPT APOE
21 cerebrovascular disease 30.2 ACHE APOE APP MAPT
22 neurodegeneration with brain iron accumulation 30.2 SNCA SNCB SNCG
23 semantic dementia 30.2 RPS27A MAPT APOE
24 pick disease of brain 30.1 SNCA RPS27A MAPT APP APOE
25 neuronal intranuclear inclusion disease 30.1 RPS27A MAPT SNCA
26 psychotic disorder 29.9 CYP2D6 MAOB SLC18A2 SLC6A3
27 alzheimer disease 29.9 SNCB SNCA PRNP MAPT MAOB BCHE
29 amyotrophic lateral sclerosis 1 29.7 APP MAOB MAPT PRNP RPS27A SNCA
30 frontotemporal dementia 29.7 SNCA RPS27A PRNP MAPT LRRK2 APP
31 supranuclear palsy, progressive, 1 29.4 TH SNCA SLC6A3 RPS27A PRKN PARK7
32 movement disease 29.4 TH SNCG SNCA SLC6A3 SLC18A2 PRKN
33 parkinson disease, late-onset 28.3 TH SNCG SNCB SNCAIP SNCA SLC6A3
34 parkinson disease 1, autosomal dominant 12.0
35 myoclonic epilepsy of lafora 11.3
36 parkinson disease 4, autosomal dominant 11.2
37 parkinson disease 5, autosomal dominant 11.2
38 parkinson disease 19a, juvenile-onset 11.1
39 parkinson disease 8, autosomal dominant 11.0
40 parkinson disease 11, autosomal dominant 11.0
41 parkinson disease 13, autosomal dominant 11.0
42 parkinson disease 17 11.0
43 parkinson disease 18, autosomal dominant 11.0
44 parkinson disease 20, early-onset 11.0
45 parkinson disease 21 11.0
46 parkinson disease 22, autosomal dominant 11.0
47 parkinson disease 23, autosomal recessive early-onset 11.0
48 mitochondrial membrane protein-associated neurodegeneration 11.0
49 hereditary late-onset parkinson disease 10.4 SNCA LRRK2 GBA
50 simultanagnosia 10.4 APOE MAPT

Graphical network of the top 20 diseases related to Dementia, Lewy Body:

Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Human phenotypes related to Dementia, Lewy Body:

33 (show all 6)
# Description HPO Frequency HPO Source Accession
1 dementia 33 HP:0000726
2 parkinsonism 33 HP:0001300
3 visual hallucinations 33 HP:0002367
4 lewy bodies 33 HP:0100315
5 delusions 33 HP:0000746
6 fluctuations in consciousness 33 HP:0007159

Symptoms via clinical synopsis from OMIM:

Neurologic Central Nervous System:
visual hallucinations
fluctuations in consciousness
progressive dementia

Clinical features from OMIM:


UMLS symptoms related to Dementia, Lewy Body:

seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, hallucinations, visual

MGI Mouse Phenotypes related to Dementia, Lewy Body:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ACHE APOE APP GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.36 ACHE APOE APP BCHE GBA LRRK2
3 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.27 ACHE APOE APP GBA MAPT PARK7
5 mortality/aging MP:0010768 10.21 ACHE APOE APP BCHE GBA LRRK2
6 nervous system MP:0003631 10.16 ACHE APOE APP GBA LRRK2 MAOB
7 cardiovascular system MP:0005385 10.15 APOE APP GBA LRRK2 MAPT PRKN
8 integument MP:0010771 10.1 APOE APP GBA LRRK2 MAPT PRKN
9 muscle MP:0005369 9.92 ACHE APOE APP MAPT PRKN PRNP
10 no phenotypic analysis MP:0003012 9.85 ACHE APOE APP LRRK2 MAPT PRKN
11 normal MP:0002873 9.65 APP GBA LRRK2 MAPT PRKN PRNP
12 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
Modafinil Approved, Investigational Phase 4,Not Applicable 68693-11-8 4236
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
Iodine Approved, Investigational Phase 4 7553-56-2 807
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Acetaminophen Approved Phase 4 103-90-2 1983
Corticosterone Experimental Phase 4 50-22-6 5753
9 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Nootropic Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Central Nervous System Stimulants Phase 4,Not Applicable
14 Wakefulness-Promoting Agents Phase 4,Not Applicable
15 Cytochrome P-450 CYP3A Inducers Phase 4,Not Applicable
16 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
17 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
20 Pharmaceutical Solutions Phase 4,Not Applicable
21 Calamus Phase 4
22 cadexomer iodine Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Fluorodeoxyglucose F18 Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Narcotic Antagonists Phase 4
27 Analgesics Phase 4
28 Analgesics, Opioid Phase 4
29 Central Nervous System Depressants Phase 4,Phase 3
30 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
31 Antipyretics Phase 4
32 Narcotics Phase 4
Galantamine Approved Phase 3 357-70-0 9651
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
35 Autonomic Agents Phase 3,Not Applicable
36 Cardiotonic Agents Phase 3,Not Applicable
37 Protective Agents Phase 3,Not Applicable
38 Sympathomimetics Phase 3,Not Applicable
39 Tranquilizing Agents Phase 3
40 Antipsychotic Agents Phase 3
41 Serotonin 5-HT2 Receptor Antagonists Phase 3
42 Psychotropic Drugs Phase 3
43 Serotonin Agents Phase 3
44 Serotonin Antagonists Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46 Dopamine agonists Phase 1, Phase 2,Phase 2,Not Applicable
Acetylcholine Approved, Investigational Not Applicable 51-84-3 187
Rivastigmine Approved, Investigational 123441-03-2 77991
Ethanol Approved 64-17-5 702
Dextromethorphan Approved 125-71-3 5362449 5360696

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
2 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
3 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
4 Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation NCT03582488 Phase 4 18F-Flortaucipir
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
8 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
9 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3 donepezil
10 Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
11 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
12 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
13 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
14 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
15 Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine Not yet recruiting NCT03858270 Phase 3 Memantine
16 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
17 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies Recruiting NCT03467152 Phase 2 E2027;Placebo
18 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
19 A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies Suspended NCT03592862 Phase 2 HTL0018318;Placebo
20 Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Recruiting NCT03888222 Phase 2 Placebo Oral Tablet;Bosutinib Oral Tablet
21 Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia Completed NCT02640729 Phase 2 Nelotanserin;Placebo
22 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
23 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
24 Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) Completed NCT00630500 Phase 2 Memantine;Placebo
25 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Active, not recruiting NCT02702102 Phase 2 11C-PBR28
26 Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Terminated NCT02871427 Phase 2 Nelotanserin
27 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Completed NCT02708186 Phase 2 Nelotanserin;Placebo
28 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
29 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
30 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Active, not recruiting NCT02450786 Phase 2 Donepezil
31 A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Not yet recruiting NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
32 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes Recruiting NCT03555292 Phase 2 11C-PiB
33 Therapy in Amyotrophic Lateral Sclerosis (TAME) Recruiting NCT02118727 Phase 2 Memantine;Placebo (for Memantine)
34 Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Completed NCT02281474 Phase 1 Nilotinib
35 Nilotinib in Huntington's Disease Recruiting NCT03764215 Phase 1 Nilotinib 150 MG
36 Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. Unknown status NCT01876459 Not Applicable
37 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628 Not Applicable
38 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Not Applicable Armodafinil
39 Movement and Music Intervention for Individuals With Dementia Unknown status NCT03121950 Not Applicable
40 Gait and REM Sleep Behavior Disorder Unknown status NCT02554331 Not Applicable
41 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
42 Understanding Hallucinations (Part II) Unknown status NCT02460965
43 Understanding Hallucinations (Part I) Unknown status NCT01907568
44 Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Completed NCT00917709 Not Applicable
45 Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies Completed NCT01340001 Not Applicable
46 Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease Recruiting NCT03019757
47 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436 Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
48 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937 Not Applicable
49 Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) Completed NCT00820937 Not Applicable
50 Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB) Completed NCT00776347 Not Applicable Donepezil;Donepezil

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 30 GBA SNCA SNCB
2 Lewy Bodies 30

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

Brain, Heart, Eye, Testes, Colon, Cortex, Small Intestine

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 194)
# Title Authors Year
Extreme sleep pattern in Lewy body dementia: a hypothalamic matter? ( 30852516 )
86 Hyperfamiliarity for Unknown Faces in a Patient with Lewy Body Dementia. ( 30859999 )
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. ( 30867052 )
Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. ( 30775974 )
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. ( 30783428 )
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. ( 30797240 )
Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. ( 30658705 )
When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. ( 29778582 )
Clinical prevalence of Lewy body dementia. ( 29448953 )
Dementia, Lewy Body ( 29494048 )
Module differences of glucose metabolic brain network among Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia and health control. ( 30440801 )
Lewy Body Dementia. ( 30336990 )
Machine learning identified an Alzheimer's disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson's disease dementia. ( 30185806 )
Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study. ( 30091150 )
Probable Lewy Body Dementia with a Predilection for Auditory Hallucinations. ( 30013866 )
Glucose Metabolic Brain Network Differences between Chinese Patients with Lewy Body Dementia and Healthy Control. ( 29854020 )
Neuroimaging in Lewy body dementia. ( 29761296 )
Occipital and Cingulate Hypometabolism are Significantly Under-Reported on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia. ( 29657900 )
Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. ( 28988547 )
Long reaction times are associated with delayed brain activity in lewy body dementia. ( 29094778 )
Non-pharmacological interventions for Lewy body dementia: a systematic review. ( 29143692 )
APOE DNA methylation is altered in Lewy body dementia. ( 29544979 )
Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer's disease patients. ( 29545639 )
ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia. ( 28088604 )
Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. ( 28391039 )
Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia. ( 28035932 )
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. ( 28269775 )
A descriptive study of Lewy body dementia with functional imaging support in a Chinese population: a preliminary study. ( 28473650 )
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia? ( 28705819 )
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia. ( 28806386 )
Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia. ( 29035934 )
Neuroleptic Malignant Syndrome Caused by Quetiapine in an Elderly Man with Lewy Body Dementia. ( 27564641 )
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. ( 26938614 )
Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. ( 27634418 )
Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. ( 27544062 )
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China. ( 26882509 )
Neural correlates of attention-executive dysfunction in lewy body dementia and Alzheimer's disease. ( 26705763 )
A faster way to diagnose Lewy body dementia. ( 27062761 )
Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. ( 27224930 )
Exercise for Individuals with Lewy Body Dementia: A Systematic Review. ( 27258533 )
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. ( 27296778 )
Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases. ( 27567844 )
Gene expression profiling of brain samples from patients with Lewy body dementia. ( 27666482 )
High dose rivastigmine in the symptom management of Lewy body dementia. ( 27899389 )
Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. ( 26250473 )
Somatoform and Conversion Disorder Preceding Lewy Body Dementia: A Newly Described Phenomenological Manifestation of the Disease. ( 26390000 )
The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. ( 26346695 )
The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease. ( 25504308 )
Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia. ( 26280289 )
Small intestine perforation due to accidental press-through package ingestion in an elderly patient with Lewy body dementia and recurrent cardiopulmonary arrest. ( 26678691 )

Variations for Dementia, Lewy Body

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

ClinVar genetic disease variations for Dementia, Lewy Body:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 GBA NM_001005741.2(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
2 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
3 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh38 Chromosome 4, 89828149: 89828149
4 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh37 Chromosome 4, 90749321: 90749321
5 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh38 Chromosome 4, 89828170: 89828170
6 SNCA SNCA, DUPLICATION duplication Pathogenic
7 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh38 Chromosome 4, 89726643: 89726643
8 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh37 Chromosome 4, 90647794: 90647794
9 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh38 Chromosome 4, 89726164: 89835687
10 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh37 Chromosome 4, 90647315: 90756838
11 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh38 Chromosome 5, 176621218: 176621218
12 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh37 Chromosome 5, 176048219: 176048219
13 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh38 Chromosome 5, 176626472: 176626472
14 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh37 Chromosome 5, 176053473: 176053473
15 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh38 Chromosome 1, 155235843: 155235843
16 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
17 GBA NM_001005741.2(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant risk factor rs421016 GRCh38 Chromosome 1, 155235252: 155235252

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 11.77 APP CYP2D6 MAOB SLC18A2
Show member pathways
11.29 ACHE SLC6A3 TH
11 11.2 ACHE APOE CYP2D6
12 11.02 SLC18A2 SLC6A3 TH
Show member pathways
15 10.7 MAOB TH
16 10.63 PRKN RPS27A
17 10.62 ACHE TH

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.99 ACHE APP PARK7 PRKN SNCA SNCG
2 dendrite GO:0030425 9.96 APOE LRRK2 MAPT PRNP TH
3 neuron projection GO:0043005 9.87 APP LRRK2 MAPT PARK7 PRKN SLC6A3
4 mitochondrial outer membrane GO:0005741 9.83 LRRK2 MAOB RPS27A SNCA
5 postsynapse GO:0098794 9.8 LRRK2 PRNP SNCA
6 synaptic vesicle GO:0008021 9.77 LRRK2 SLC18A2 SNCA SNCAIP TH
7 growth cone GO:0030426 9.76 APP LRRK2 MAPT SNCA
8 synaptic vesicle membrane GO:0030672 9.74 LRRK2 SLC18A2 SNCA
9 presynapse GO:0098793 9.73 PARK7 PRKN SNCA SNCB
10 membrane raft GO:0045121 9.73 APP LRRK2 MAPT PARK7 PRNP SLC6A3
11 terminal bouton GO:0043195 9.71 LRRK2 SLC18A2 SNCA TH
12 synaptic cleft GO:0043083 9.6 ACHE APOE
13 dopaminergic synapse GO:0098691 9.59 SLC18A2 SLC6A3
14 neuronal cell body GO:0043025 9.56 APOE LRRK2 MAPT SLC6A3 SNCA SNCAIP
15 nuclear envelope lumen GO:0005641 9.55 APP BCHE
16 main axon GO:0044304 9.54 APP MAPT
17 inclusion body GO:0016234 9.46 LRRK2 PRNP SNCA SNCB
18 axon GO:0030424 9.23 APP LRRK2 MAPT PARK7 SLC6A3 SNCA
19 membrane GO:0016020 10.48 ACHE APOE APP BCHE CYP2D6 GBA
20 cytoplasm GO:0005737 10.35 APOE APP CYP2D6 LRRK2 MAPT PARK7
21 extracellular space GO:0005615 10.19 ACHE APOE APP BCHE GBA LRRK2
22 endoplasmic reticulum GO:0005783 10.16 APOE BCHE CYP2D6 LRRK2 PARK7 PRKN
23 Golgi apparatus GO:0005794 10.12 ACHE APOE APP LRRK2 PRKN PRNP
24 mitochondrion GO:0005739 10.1 CYP2D6 LRRK2 MAOB MAPT PARK7 PRKN
25 synapse GO:0045202 10.01 ACHE APP LRRK2 SNCA SNCB

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.97 APOE APP PRKN RPS27A SNCA SNCAIP
2 negative regulation of neuron apoptotic process GO:0043524 9.95 APOE PARK7 PRKN SNCA SNCB
3 response to ethanol GO:0045471 9.92 MAOB SLC6A3 TH
4 response to oxidative stress GO:0006979 9.91 APOE APP LRRK2 PRKN PRNP
5 cellular response to oxidative stress GO:0034599 9.9 LRRK2 PARK7 SNCA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 APP PARK7 SNCA
7 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.88 GBA LRRK2 PRKN
8 mitochondrion organization GO:0007005 9.88 GBA LRRK2 PARK7 PRKN
9 locomotory behavior GO:0007626 9.88 APP PRKN SLC18A2 SLC6A3 TH
10 positive regulation of protein binding GO:0032092 9.86 APP LRRK2 PRKN
11 regulation of autophagy GO:0010506 9.86 LRRK2 MAPT PRKN
12 learning GO:0007612 9.86 APP BCHE PRKN TH
13 negative regulation of protein phosphorylation GO:0001933 9.83 LRRK2 PARK7 PRKN PRNP SNCA
14 protein destabilization GO:0031648 9.82 PRKN PRNP SNCA
15 positive regulation of neuron death GO:1901216 9.8 MAPT PRNP SNCA
16 regulation of dopamine secretion GO:0014059 9.78 PRKN SNCA SNCG
17 cellular response to copper ion GO:0071280 9.77 APP PRNP SNCA
18 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.75 LRRK2 PARK7 PRKN
19 microglial cell activation GO:0001774 9.74 MAPT SNCA
20 response to metal ion GO:0010038 9.74 SNCB TH
21 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.74 APP PRNP
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 LRRK2 PARK7
23 cellular copper ion homeostasis GO:0006878 9.74 APP PRNP
24 neurotransmitter biosynthetic process GO:0042136 9.74 ACHE SLC6A3 TH
25 cellular response to dopamine GO:1903351 9.73 LRRK2 PRKN
26 locomotory exploration behavior GO:0035641 9.73 APOE LRRK2
27 negative regulation of protein processing GO:0010955 9.73 LRRK2 PRNP
28 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.73 PARK7 SLC18A2
29 supramolecular fiber organization GO:0097435 9.73 MAPT SNCA
30 regulation of protein metabolic process GO:0051246 9.72 APOE GBA
31 amyloid precursor protein metabolic process GO:0042982 9.72 ACHE APOE
32 virion assembly GO:0019068 9.72 APOE RPS27A
33 adult locomotory behavior GO:0008344 9.72 APP PARK7 PRKN SNCA SNCG
34 astrocyte activation GO:0048143 9.71 APP MAPT
35 negative regulation of amyloid-beta formation GO:1902430 9.71 APOE PRNP
36 neuron projection maintenance GO:1990535 9.71 APP PRNP
37 neurotransmitter catabolic process GO:0042135 9.71 ACHE MAOB
38 positive regulation of protein metabolic process GO:0051247 9.71 APP GBA
39 dopamine biosynthetic process GO:0042416 9.71 SLC6A3 SNCA TH
40 regulation of neurotransmitter secretion GO:0046928 9.71 PRKN SNCA SNCAIP SNCG
41 regulation of dopamine metabolic process GO:0042053 9.7 PRKN SLC6A3
42 amyloid fibril formation GO:1990000 9.7 APP MAPT
43 intracellular distribution of mitochondria GO:0048312 9.7 LRRK2 MAPT
44 negative regulation of long-term synaptic potentiation GO:1900272 9.7 APOE APP PRNP
45 monoamine transport GO:0015844 9.69 SLC18A2 SLC6A3
46 positive regulation of microglial cell activation GO:1903980 9.69 APP LRRK2
47 regulation of locomotion GO:0040012 9.69 LRRK2 SNCA
48 dopamine catabolic process GO:0042420 9.68 MAOB SLC6A3
49 mating behavior GO:0007617 9.68 APP TH
50 regulation of mitochondrial fission GO:0090140 9.67 LRRK2 MAPT

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.81 LRRK2 MAPT PRNP SNCA
2 chaperone binding GO:0051087 9.74 MAPT PRKN PRNP
3 enzyme binding GO:0019899 9.7 APP BCHE MAPT PARK7 PRKN SNCA
4 copper ion binding GO:0005507 9.65 PARK7 PRNP SNCA
5 identical protein binding GO:0042802 9.65 APOE APP BCHE LRRK2 MAPT PARK7
6 amyloid-beta binding GO:0001540 9.62 ACHE APOE BCHE PRNP
7 tau protein binding GO:0048156 9.58 APOE SNCA
8 ubiquitin-specific protease binding GO:1990381 9.56 PARK7 PRKN
9 tubulin binding GO:0015631 9.56 LRRK2 MAPT PRKN PRNP
10 phospholipase binding GO:0043274 9.55 PRKN SNCA
11 dopamine binding GO:0035240 9.54 SLC6A3 TH
12 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A3
13 lipoprotein particle binding GO:0071813 9.46 APOE MAPT
14 cupric ion binding GO:1903135 9.43 PARK7 PRNP
15 cholinesterase activity GO:0004104 9.4 ACHE BCHE
16 acetylcholinesterase activity GO:0003990 9.37 ACHE BCHE
17 cuprous ion binding GO:1903136 8.92 PARK7 PRNP SNCA SNCB
18 protein homodimerization activity GO:0042803 10 ACHE APOE LRRK2 MAOB MAPT PARK7

Sources for Dementia, Lewy Body

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....